Once operations resumed, decrease seen in new patients screened, proportion of suspicious nodules increased

Pulmonary complication, postoperative SARS-CoV-2 infection rates lower with COVID-19-free pathways

Use of ACE-I/ARB versus nonuse linked to lower mortality for those hospitalized with flu, pneumonia

No infection identified among surgeons following procedure; postoperative complications rarely seen

However, no significant difference in mortality found between remdesivir and placebo groups

No reductions seen in 28-day mortality or duration of hospital stay in COVID-19 with lopinavir-ritonavir

If enough people in the U.S. pass on vaccine, the nation may not be able to achieve herd immunity

No clinical benefit seen versus placebo for hospital-based health care workers exposed to patients with COVID-19

Higher case fatality rates found to be independent of demographic factors, such as age, sex, and race

Agency says it is especially true in enclosed spaces with inadequate ventilation